Update to Vaccination Guidelines  by Ljungman, Per & Small, Trudy N.
LETTERS TO THE EDITORD-index and Prediction of
Infection
We read with interest the article ‘‘Retrospective
Evaluation of the Area Over the Neutrophil Curve
Index to Predict Early Infection in Hematopoietic
Stem Cell Transplantation Recipients’’ by Kimura
et al. [1]. In this article, they evaluated the impact of
the D-index and the cumulative D-index (c-D-index)
on the early development of bloodstream infections
(BSI) and pulmonary infections after autologous and
allogeneic hematopoietic stem cell transplantation,
and compared the D-index with total duration of
neutropenia (\500/mL), total duration of profound
neutropenia (\100/mL), cumulative duration of neu-
tropenia, and cumulative duration of profound neutro-
penia. None of the cumulative indexes was predictive
of BSI. This problably happened because most BSIs
tend to occur early in the course of neutropenia, and
duration neutropenia may not be a major determinant
of the risk of BSI in such patients. By contrast, both the
D-index and the c-D-index predicted pulmonary in-
fections. Interestingly enough, they found that a cutoff
of 5500 for the c-D-index was predictive of pulmonary
infections, a value comparable to our cutoff of 5800
for invasive mold infections [2], suggesting that most
cases of pneumonia in the present study were of fungal
origin.
Conceptually, the c-D-index should work as a risk
factor for late events occurring during neutropenia.
This was true for invasive mold infections, as we
reported in our study [2], and perhaps breakthrough
(but not early) bacteremias, another event that typi-
cally occurs later during neutropenia [3]. Therefore,
we are not surprised that the c-D-index did not work
for BSI in the present study.
What the c-D-index may add to simple cumula-
tive duration of neutropenia is its ability to discrimi-
nate between patients with the same duration but
different intensities of neutropenia. If we observe
the regression curve (linear) of D-index and duration
of neutropenia, many points do not fit the regression
line. For example, in our article, we found one pa-
tient with 14 days of neutropenia and a D-index of
5395 and another with 21 days of neutropenia and
a D-index of 4531 [2]. In such a case, the D-index
may discriminate better than the duration of neutro-
penia. The role of the D-index as a tool in neutro-
penic patients either as risk factor for infection or as
a prognostic marker remains to be clarified, as well as1608the situations where it equals the more simple dura-
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Update to Vaccination
Guidelines
Last year several scientific organizations collabo-
rated in the production of guidelines for prevention
of infections after hematopoietic stem cell transplanta-
tion (HCT) [1,2]. One set of guidelines dealt with
vaccination of transplant recipients, and in these
guidelines the conjugated heptavalent pneumococcal
vaccine (PCV7; Prevnar; Pfizer, Inc. New York) was
recommended based on several studies showing
both immunogenicity and safety of this vaccine in
HCT recipients. Earlier this year, a 13-valent vaccine
(Prevnar13; Pfizer, Inc.), which is produced in a similar
way to the 7-valent vaccine, was licensed in both the
United States and Europe after the completion of large
clinical trials in healthy children. This vaccine contains
the same 7 pneumococcal serotype antigens contained
in the PCV7, together with antigens from additional
6 serotypes. After licensure, it was decided that the
heptavalent vaccine will be withdrawn from the market,
and therefore the published recommendations cannot
be followed. Presently a clinical trial is ongoing with
this 13-valent vaccine in allogeneic HCT recipients. In
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GSK, Brentford, UK) conjugated to another carrier
protein has also been licensed in Europe for which no
data yet exists in immunocompromised patients.
The alternative to these conjugated vaccines are
polysaccharide vaccines that have shown decreased
immunogenicity compared to conjugate vaccines in
allogeneic HSCT recipients. Despite the lack of data,
we recommend that the 13-valent vaccine be used as
replacement for the heptavalent vaccine when this is
no longer available until additional studies have been
performed.
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